Scholarlink

<p>Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, symptoms, cytopenias, and chronic inflammation. PMF has two stages: pre-fibrotic (prePMF) and overt PMF. PrePMF and essential thrombocythemia share a similar high thrombotic risk, but few studies have examined thrombosis risk factors in prePMF. The neutrophil-to-lymphocyte ratio (NLR), reflecting the imbalance between systemic inflammation and immunity, has emerged as a prognostic biomarker in various diseases. We investigated the predictive value of NLR for thrombotic risk in a multicenter cohort of 225 prePMF patients enrolled in the retro-prospective observational INFLA-ME (INFLAmmation in MyeloproliferativE disease) cooperative study. After a median follow-up of 5.9 years, 37 thrombotic events occurred in 31 patients (2.5 events/100 patients/year; 18 arterial, 19 venous). Multivariate analysis linked venous thrombosis risk to prior venous events (HR 4.46, <i>p</i> = 0.001) and NLR ≥ 6 (HR 3.82, <i>p</i> = 0.008). The patients with NLR ≥ 6 showed a shorter venous thrombosis-free survival (<i>p</i> = 0.003). NLR value had no significant association with total and arterial thrombotic events. In conclusion, NLR is an inexpensive and accessible prognostic biomarker of venous thrombosis in prePMF. The integration of NLR into conventional risk scores may allow for better identification of pre-PMF patients requiring cytoreduction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • Fabrizio Cavalca,
  • Roberto Latagliata,
  • Novella Pugliese,
  • Giuseppe Alberto Palumbo,
  • Nicola Polverelli,
  • Pellegrino Musto,
  • Giulia Benevolo,
  • Filippo Branzanti,
  • Ambra Di Veroli,
  • Eugenia Accorsi Buttini,
  • Alessia Ripamonti,
  • Ivan Civettini,
  • Laura Montelisciani,
  • Laura Antolini,
  • Carlo Gambacorti-Passerini,
  • Francesca Palandri,
  • Elena Maria Elli

摘要

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, symptoms, cytopenias, and chronic inflammation. PMF has two stages: pre-fibrotic (prePMF) and overt PMF. PrePMF and essential thrombocythemia share a similar high thrombotic risk, but few studies have examined thrombosis risk factors in prePMF. The neutrophil-to-lymphocyte ratio (NLR), reflecting the imbalance between systemic inflammation and immunity, has emerged as a prognostic biomarker in various diseases. We investigated the predictive value of NLR for thrombotic risk in a multicenter cohort of 225 prePMF patients enrolled in the retro-prospective observational INFLA-ME (INFLAmmation in MyeloproliferativE disease) cooperative study. After a median follow-up of 5.9 years, 37 thrombotic events occurred in 31 patients (2.5 events/100 patients/year; 18 arterial, 19 venous). Multivariate analysis linked venous thrombosis risk to prior venous events (HR 4.46, p = 0.001) and NLR ≥ 6 (HR 3.82, p = 0.008). The patients with NLR ≥ 6 showed a shorter venous thrombosis-free survival (p = 0.003). NLR value had no significant association with total and arterial thrombotic events. In conclusion, NLR is an inexpensive and accessible prognostic biomarker of venous thrombosis in prePMF. The integration of NLR into conventional risk scores may allow for better identification of pre-PMF patients requiring cytoreduction.